183 related articles for article (PubMed ID: 33864599)
1. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.
Chakraborty D; Stewart MW; Sheth JU; Sinha TK; Boral S; Das A; Mondal S; Mukherjee A
Ophthalmol Ther; 2021 Jun; 10(2):337-348. PubMed ID: 33864599
[TBL] [Abstract][Full Text] [Related]
2. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.
Soman M; Nair I; Sheth JU; Nair U
Ophthalmol Ther; 2022 Jun; 11(3):1175-1186. PubMed ID: 35412266
[TBL] [Abstract][Full Text] [Related]
3. Razumab -- the role of biosimilars for the treatment of retinal diseases.
Ferro Desideri L; Cutolo CA; Traverso CE; Nicolò M
Drugs Today (Barc); 2021 Aug; 57(8):499-505. PubMed ID: 34405207
[TBL] [Abstract][Full Text] [Related]
4. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
5. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Sharma S; Sharma T; Prasad S; Gopalakrishnan M; Chaturvedi A
Ophthalmol Ther; 2021 Sep; 10(3):431-443. PubMed ID: 34155608
[TBL] [Abstract][Full Text] [Related]
6. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
[TBL] [Abstract][Full Text] [Related]
8. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
9. Safety of 5914 intravitreal ziv-aflibercept injections.
Singh SR; Stewart MW; Chattannavar G; Ashraf M; Souka A; ElDardeery M; Wadhwa N; Sarvaiya C; Mansour AM; Marashi A; Ramchandani S; Braimah IZ; Jabbarpoor Bonyadi MH; Ramezani A; Soheilian M; de Oliveira Dias JR; de Andrade GC; Maia A; Rodrigues EB; Farah ME; Banker A; Chhablani J;
Br J Ophthalmol; 2019 Jun; 103(6):805-810. PubMed ID: 30099379
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
11. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
12. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
Kataja M; Hujanen P; Huhtala H; Kaarniranta K; Tuulonen A; Uusitalo-Jarvinen H
Br J Ophthalmol; 2018 Jul; 102(7):959-965. PubMed ID: 29074495
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
[TBL] [Abstract][Full Text] [Related]
14. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.
Sharma S; Johnson D; Abouammoh M; Hollands S; Brissette A
Can J Ophthalmol; 2012 Jun; 47(3):275-9. PubMed ID: 22687306
[TBL] [Abstract][Full Text] [Related]
15. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
16. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
17. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.
Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M
Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
19. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
20. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
